In early-phase trials, personalized neoantigen vaccines combined with anti–PD-1 therapy elicited tumor-specific T-cell responses in advanced melanoma, NSCLC, and bladder cancer, with accurate HLA matching proving critical. The gene discussed is SNCA; the disease is non-small cell lung carcinoma.